Top Page
Disc Medicine
(NASDAQ:IRON)
Disc Medicine (IRON) vs. SPDR S&P 500 ETF (SPY)
Disc Medicine Business Overview & Revenue Model
Disc Medicine Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -281.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -207.94M | -108.27M | -76.23M | -47.39M | -30.90M |
| Net Income | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M |
Balance Sheet | |||||
| Total Assets | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M |
| Cash, Cash Equivalents and Short-Term Investments | 791.15M | 489.88M | 360.38M | 194.61M | 88.04M |
| Total Debt | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M |
| Total Liabilities | 67.05M | 53.19M | 22.88M | 23.61M | 156.61M |
| Stockholders Equity | 739.83M | 443.59M | 345.12M | 176.60M | -64.20M |
Cash Flow | |||||
| Free Cash Flow | -181.33M | -94.43M | -73.55M | -42.40M | -27.60M |
| Operating Cash Flow | -180.39M | -93.93M | -73.46M | -42.25M | -27.53M |
| Investing Cash Flow | -394.30M | -292.33M | -89.00K | -151.00K | -68.00K |
| Financing Cash Flow | 473.41M | 218.31M | 239.38M | 148.98M | 89.93M |
Disc Medicine Technical Analysis
Disc Medicine Risk Analysis
Disc Medicine Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $3.07B | -176.98 | -9.30% | ― | 129.21% | 80.35% | |
62 Neutral | $3.30B | -48.10 | -23.39% | ― | 182.44% | 47.21% | |
53 Neutral | $1.89B | -2.45 | -59.54% | ― | -32.98% | -18.46% | |
52 Neutral | $1.71B | -4.10 | -30.20% | ― | 36.26% | -158.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.72B | -48.97 | -57.80% | ― | 114.22% | 77.02% | |
43 Neutral | $2.54B | ― | -35.86% | ― | ― | -34.96% |
Disc Medicine Corporate Events
On February 26, 2026, Disc Medicine, Inc.’s board approved a restructuring plan and management began implementation to better align its workforce with near-term strategic priorities after receiving a complete response letter from the U.S. Food and Drug Administration on February 13, 2026 regarding its New Drug Application for bitopertin. The plan includes a workforce reduction of about 20%, focused mainly on commercial and certain support functions, with implementation expected to be completed in the second quarter of 2026.
Disc Medicine expects to incur approximately $2.0 million in aggregate charges, largely severance-related, which will be recorded primarily in the first quarter of 2026. The restructuring highlights the operational and financial impact of the FDA’s response on the company’s commercial readiness and may signal a shift in resource allocation while introducing uncertainty around potential additional costs linked to the plan.
The most recent analyst rating on (IRON) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.
Disc Medicine, Inc., a biopharmaceutical company developing therapies for hematologic diseases including rare conditions like erythropoietic protoporphyria, is advancing a pipeline led by bitopertin alongside other candidates such as DISC-0974 and DISC-3405. Its development strategy focuses on robust clinical trial design and regulatory engagement to secure approval for treatments in areas of high unmet medical need.
On February 17, 2026, Disc Medicine planned a conference call to address a Complete Response Letter the U.S. Food and Drug Administration issued on February 13, 2026, rejecting its accelerated approval bid for bitopertin in erythropoietic protoporphyria over concerns that reductions in protoporphyrin IX had not been shown to reliably predict clinical benefit. The FDA requested additional clinical endpoint evidence, indicating it wants to see results from the ongoing Phase 3 APOLLO trial and updated safety data before reconsidering, prompting Disc to prioritize completing APOLLO enrollment by March 2026 and delivering topline data in the fourth quarter of 2026 for use in a resubmission.
The FDA’s stance underscores a higher evidentiary bar for approval, potentially delaying bitopertin’s market entry but clarifying the regulatory path and placing greater emphasis on APOLLO’s co-primary endpoints that link biomarker reductions to improvements in sunlight tolerance. For investors and patients, the outcome of APOLLO has become a pivotal inflection point for Disc’s EPP program and its broader positioning in the rare disease hematology space, as successful data could both satisfy regulators and validate the company’s biomarker-driven approach.
The most recent analyst rating on (IRON) stock is a Buy with a $118.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.
Disc Medicine reported that on February 13, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for bitopertin as a treatment for erythropoietic protoporphyria, halting its bid for accelerated approval. The FDA agreed Phase 2 AURORA and BEACON data showed bitopertin significantly lowers the PPIX biomarker, but found no sufficient evidence that reductions in PPIX translated into improved sunlight-exposure outcomes in those trials.
Regulators indicated they want to see results from the ongoing Phase 3 APOLLO study before considering traditional approval, effectively pushing any U.S. decision on bitopertin into at least mid-2027. Disc, which completed APOLLO enrollment earlier than expected and held about $791 million in cash and securities at year-end 2025, plans a Type A meeting with the FDA and maintains it has funding runway into 2029, tempering near-term regulatory disappointment with longer-term development and liquidity visibility.
The most recent analyst rating on (IRON) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.
On January 12, 2026, Disc Medicine highlighted 2025 as a transformative year in which it submitted and secured priority review for a U.S. new drug application for bitopertin, received a Commissioner’s National Priority Review Voucher, reported positive initial Phase 2 data for DISC-0974 in myelofibrosis-related anemia, advanced DISC-3405 into proof-of-concept studies, and strengthened its balance sheet to $791 million in cash and securities as of December 31, 2025, providing runway into 2029. For 2026, the company outlined plans centered on an anticipated FDA decision and potential U.S. launch of bitopertin for erythropoietic protoporphyria, continued enrollment of the APOLLO confirmatory trial, Phase 2 progression and regulatory interactions for DISC-0974 including expansion into inflammatory bowel disease–associated anemia, and continued Phase 2 and Phase 1b development of DISC-3405 in polycythemia vera and sickle cell disease, positioning Disc to transition into a fully integrated clinical and commercial hematology player.
The most recent analyst rating on (IRON) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.
On December 7, 2025, Disc Medicine held a conference call to discuss its data presented at the 67th American Society of Hematology Annual Meeting and its operational plans. The company is advancing its investigational agents, with bitopertin selected for the FDA’s Commissioner’s National Priority Voucher Pilot Program, potentially accelerating its approval and launch by January 2026. The company is also progressing with clinical trials for DISC-0974 and DISC-3405, aiming to address a range of hematologic disorders, which could significantly impact its market positioning and stakeholder interests.
The most recent analyst rating on (IRON) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Disc Medicine stock, see the IRON Stock Forecast page.